Vertex acquires Crinetics for $10B to expand into rare endocrine diseases
Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals on July 6, 2026, paying $85 per share in cash (a ~102% premium). The deal adds Palsonify, an FDA-approved oral therapy for acromegaly, and atumelnant, a late-stage drug for congenital adrenal hyperplasia, with combined peak sales potential exceeding $5 billion. Vertex expects the deal to close in Q3 2026, funded by cash and debt.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Source updates only; analysis pending
Analysis pending
Cross-source coverage
Wire timeline
Vertex to Acquire Crinetics Pharmaceuticals in $85 Per Share Cash Deal
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals (NASDAQ: CRNX) for $85 per share in cash, valuing the deal at approximately $10 billion, or $8.8 billion net of cash. The transaction, approved unanimously by both boards, is expected to close in the third quarter of 2026. Vertex will finance the acquisition using cash on hand and $4.5 billion in bridge financing from Bank of America and Morgan Stanley. Crinetics focuses on treatments for rare endocrine diseases and endocrine-related tumors, with pipeline assets including Paltusotine, Atumelnant, and oral GLP-1/GIP nonpeptide therapies. Following the announcement, analysts offered mixed views: Baird raised its price target to $85 with an Outperform rating, while Evercore ISI downgraded the stock to In Line with an $85 target. The article also notes that the author considers certain AI stocks to offer greater upside potential.
Vertex to Acquire Crinetics Pharmaceuticals in $85 Per Share Cash Deal
On July 6, 2026, Vertex Pharmaceuticals and Crinetics Pharmaceuticals announced a definitive agreement for Vertex to acquire Crinetics for $85 per share in cash, valuing the deal at approximately $10 billion ($8.8 billion net of cash). Both boards unanimously approved the transaction, with completion expected in Q3 2026. Vertex plans to finance the acquisition using cash on hand and $4.5 billion in bridge financing from Bank of America and Morgan Stanley. Analysts reacted with mixed opinions: Baird raised its price target to $85 with an Outperform rating, while Evercore ISI downgraded the stock to In Line with a $85 target. Crinetics focuses on treatments for rare endocrine diseases and tumors, with pipeline candidates including Paltusotine, Atumelnant, and oral GLP-1/GIP nonpeptide therapies.
Vertex Pays Over 100% Premium for Crinetics Pharmaceuticals Due to Promising CAH Drug
Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals, paying a 102% premium. The deal was driven by Vertex's enthusiasm for Crinetics' experimental drug atumelnant, a once-daily pill for congenital adrenal hyperplasia (CAH) that showed strong clinical trial results. Vertex CEO Dr. Reshma Kewalramani stated the data was 'floored' and that the drug could transform CAH treatment. Vertex funded the acquisition with cash, avoiding debt. Despite the strategic rationale, Vertex shares fell from ~$530 to ~$485 following the announcement, reflecting investor apprehension about the high price. The article concludes that the acquisition could be a good long-term growth move for Vertex.
Show 16 older updatesHide older updates
Vertex Pays Over 100% Premium for Crinetics Pharmaceuticals Due to Promising CAH Drug
Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals, paying a 102% premium. The deal was driven by Vertex's enthusiasm for Crinetics' experimental drug atumelnant, a once-daily pill for congenital adrenal hyperplasia (CAH) that showed strong clinical trial results. Vertex CEO Dr. Reshma Kewalramani stated the data was 'floored' and the drug could transform CAH treatment. Vertex funded the deal with cash, avoiding debt. Despite the premium, Vertex's stock fell from ~$530 to ~$485 after the announcement, reflecting investor apprehension. The article argues the acquisition is a low-risk growth move for Vertex, potentially adding $5 billion in revenue.
Vertex Pharmaceuticals Acquires Crinetics for $10 Billion to Build Endocrinology Franchise
Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, valuing the deal at approximately $10 billion in equity ($8.8 billion net of cash). The acquisition, expected to close in Q3 2026, is a strategic move to build an endocrinology powerhouse. The deal centers on two key assets: PALSONIFY, an approved once-daily oral therapy for acromegaly launched in the U.S. in October 2025, and atumelnant, a late-stage treatment for congenital adrenal hyperplasia (CAH). Vertex believes these could generate over $5 billion in combined peak annual sales. Vertex plans to finance the purchase with cash and debt, including $4.5 billion in committed bridge financing. Management expects the deal to be modestly dilutive near-term but accretive to non-GAAP operating income by 2029, while noting development and safety risks for atumelnant.
Vertex Pharmaceuticals Acquires Crinetics for $10 Billion to Build Endocrinology Franchise
Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals, paying $85 per share in cash, to expand into specialty endocrinology. The deal, expected to close in Q3 2026, centers on two key assets: PALSONIFY, an approved once-daily oral therapy for acromegaly, and atumelnant, a late-stage treatment for congenital adrenal hyperplasia (CAH). Vertex projects combined peak annual sales exceeding $5 billion. PALSONIFY, launched in the U.S. in October 2025, generated $10.3 million in Q1 2026 revenue and achieved 40-50% new-to-brand prescription share. Vertex plans to finance the purchase with cash and $4.5 billion in bridge debt, expecting the deal to be accretive to non-GAAP operating income by 2029. Management highlighted strong early uptake and payer coverage for PALSONIFY, while noting development and safety risks for atumelnant.
Crinetics Pharmaceuticals Stock Surges 98% on $10 Billion Vertex Acquisition
Shares of Crinetics Pharmaceuticals (NASDAQ: CRNX) surged nearly 100% this week following the announcement that Vertex Pharmaceuticals will acquire the company for $10 billion in cash. The acquisition price is $85 per share, and the stock is trading just below that level at $83.62. Crinetics, which received FDA approval for its drug Palsonify (an oral treatment for Acromegaly) in September 2025, also has a pipeline of other drugs in clinical trials. Vertex aims to use the acquisition to diversify beyond its dominant cystic fibrosis market into rare diseases, with combined assets potentially generating $5 billion in annual revenue. The article advises investors to sell Crinetics shares and seek other opportunities, as the implied returns are now similar to treasury bonds.
Crinetics Stock Soars 99% on Vertex's $10 Billion Acquisition Bid
Crinetics Pharmaceuticals (CRNX) stock surged 99% this week after Vertex Pharmaceuticals (VRTX) agreed to acquire it for $85 per share in an all-cash deal valued at approximately $10 billion. The acquisition, expected to close in Q3 2026, gives Vertex access to Crinetics' endocrine franchise, including PALSONIFY (paltusotine), a recently approved once-daily oral treatment for acromegaly, and atumelnant, a Phase 3 candidate for congenital adrenal hyperplasia and Cushing's syndrome. Vertex projects the acquired assets could generate over $5 billion in peak annual sales and contribute earnings accretion by 2029. The deal also triggered a re-rating of endocrine rare-disease peers, with Neurocrine Biosciences (NBIX) gaining 6.24%, Corcept Therapeutics (CORT) rising 5.04%, and Ascendis Pharma (ASND) up 3.51%, as investors view them as potential M&A targets. CRNX shares now trade just under the $85 offer price, limiting upside unless a competing bid emerges.
Crinetics Stock Soars 99% After Vertex Announces $10 Billion Acquisition
Crinetics Pharmaceuticals (NASDAQ:CRNX) shares surged 99% this week, from $42.03 to $83.54, following Vertex Pharmaceuticals' (NASDAQ:VRTX) announcement of an all-cash acquisition for approximately $10 billion, or $85.00 per share. The deal, unanimously approved by both boards and expected to close in Q3 2026, gives Vertex access to Crinetics' endocrine franchise, including PALSONIFY (paltusotine), a once-daily oral treatment for acromegaly approved by the FDA in September 2025 and by the European Commission in April 2026. Vertex projects the acquired assets could generate over $5 billion in peak annual sales and contribute earnings accretion by 2029. The acquisition also sparked a re-rating of endocrine rare-disease peers, with Neurocrine Biosciences (NBIX) gaining 6.24%, Corcept Therapeutics (CORT) rising 5.04%, and Ascendis Pharma (ASND) adding 3.51% as investors identified them as potential M&A targets. Vertex shares remained nearly flat, reflecting caution about the price tag.
Crinetics Pharmaceuticals Stock: Buying Opportunity After 44% Pullback and Vertex Acquisition
Crinetics Pharmaceuticals (CRNX) is highlighted as a potential buying opportunity after a 44% decline since mid-January. UBS analyst Ashwani Verma initiated coverage with a Buy rating and $55 price target, citing strong pipeline catalysts including the Phase 3 atumelnant program for congenital adrenal hyperplasia with projected peak sales of $2 billion. On July 6, Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics for $85 per share in cash, valuing the company at approximately $10 billion. The acquisition, approved by both boards, is expected to close in Q3 2026. Crinetics is a clinical-stage biopharmaceutical company developing oral non-peptide therapies for endocrine diseases, with approved drug PALSONIFY for acromegaly and pipeline assets for conditions like Cushing's syndrome and Graves' disease. The combined portfolio is projected to generate over $5 billion in peak annual revenue.
Crinetics Pharmaceuticals Stock: Buying Opportunity After 44% Pullback and Vertex Acquisition
Crinetics Pharmaceuticals (CRNX) is highlighted as a potential buying opportunity after a 44% stock decline since mid-January 2026. UBS analyst Ashwani Verma initiated coverage with a Buy rating and $55 price target, citing strong pipeline catalysts including the Phase 3 atumelnant program for congenital adrenal hyperplasia with $2 billion peak sales potential. On July 6, 2026, Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics for $85 per share in cash, valuing the company at approximately $10 billion. The deal, approved by both boards, is expected to close in Q3 2026. Crinetics focuses on oral non-peptide therapies for endocrine diseases, with approved drug PALSONIFY for acromegaly and pipeline assets for Cushing's syndrome, Graves' disease, and obesity.
Vertex's Crinetics Deal Balances Growth with Integration Risk
Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals, paying $85 per share in cash, expected to close in Q3 2026. The deal adds PALSONIFY, an approved acromegaly treatment, and Atumelant, a Phase 3 candidate for congenital adrenal hyperplasia, expanding Vertex's rare disease pipeline beyond its core cystic fibrosis franchise. Crinetics shares surged ~98% on the news. Analysts have not yet rerated Vertex shares, though H.C. Wainwright maintains a Buy rating with a $641 price target. The article discusses how big pharma continues to pay premiums for de-risked biotech assets, and notes that while Vertex gains immediate revenue from PALSONIFY, integration risks remain. The broader biotech sector may see increased M&A activity due to patent cliffs at large pharmaceutical companies.
Vertex Pays 102% Premium to Acquire Crinetics for $10 Billion
Vertex Pharmaceuticals announced it will acquire Crinetics Pharmaceuticals for $85 per share in cash, valuing the deal at approximately $10 billion (or $8.8 billion net of Crinetics' cash). The 102% premium reflects Vertex's interest in Crinetics' recently FDA-approved drug Palsonify for acromegaly, which generated $10.7 million in its first full quarter, and its late-stage pipeline candidate atumelnant for congenital adrenal hyperplasia (CAH), which Vertex believes has multi-billion dollar potential. Both boards have unanimously approved the deal, expected to close in Q3 2026. Vertex's CEO highlighted the opportunity to build on Palsonify's launch momentum and transform CAH treatment. The article analyzes whether the high premium is justified by Crinetics' commercial and pipeline assets.
Crinetics Stock Soars 99% After Vertex Agrees to $10 Billion Takeover Deal
Crinetics Pharmaceuticals stock surged 99% on Tuesday after Vertex Pharmaceuticals announced a $10 billion acquisition deal late Monday. The takeover agreement sent shares of Crinetics soaring, reflecting investor enthusiasm for the transaction. Vertex, a major biotech firm, is acquiring Crinetics to expand its pipeline. The deal highlights ongoing consolidation in the biotech sector, with large players acquiring smaller firms with promising drug candidates. The article, published by Barron's and syndicated on Yahoo Finance, provides brief details on the acquisition and its immediate market impact.
Vertex Acquires Crinetics for $10 Billion, Sees Over $5 Billion Peak Sales Potential
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $85 per share in cash, representing an equity value of approximately $10 billion ($8.8 billion net of cash). The deal, approved by both boards, is expected to close in the third quarter of 2026. Vertex will finance the acquisition through cash on hand and debt, supported by $4.5 billion in bridge financing. The acquisition adds Crinetics' marketed drug Palsonify (paltusotine), a once-daily oral therapy for acromegaly approved by the FDA in September 2025, and atumelnant, a Phase 3 candidate for congenital adrenal hyperplasia (CAH). Vertex expects the combined assets to deliver over $5 billion in peak annual revenue, contributing immediately to revenue growth via Palsonify's launch. The transaction is expected to become accretive to adjusted operating income by 2029. Analyst William Blair noted the deal's premium is reasonable if peak sales are achieved, with more risk weighted toward atumelnant.
Vertex signs agreement to acquire Crinetics for $10bn
Vertex Pharmaceuticals has signed a definitive agreement to acquire Crinetics Pharmaceuticals for approximately $10 billion, or $8.8 billion net of cash acquired. The deal, approved unanimously by both companies' boards, values Crinetics at $85.00 per share in cash. It is expected to close in Q3 2026, subject to regulatory and shareholder approvals. The acquisition adds two key endocrinology assets to Vertex's portfolio: palsonify (paltusotine), a once-daily oral therapy for acromegaly approved by the FDA in September 2025 and the EMA in April 2026, and atumelnant, a Phase III candidate for congenital adrenal hyperplasia (CAH) with potential in Cushing's syndrome. The combined peak sales potential of these assets is estimated to exceed $5 billion. Vertex will fund the deal via cash and debt, with $4.5 billion in bridge financing from Bank of America and Morgan Stanley. Vertex CEO Reshma Kewalramani emphasized the strategic fit, citing serious specialty diseases with unmet need and best-in-class medicine potential.
Vertex signs agreement to acquire Crinetics for $10bn
Vertex Pharmaceuticals has signed a definitive agreement to acquire Crinetics Pharmaceuticals for approximately $10 billion, or $8.8 billion net of estimated cash acquired. The deal, approved unanimously by both boards, will see Vertex pay $85.00 per share in cash for all outstanding Crinetics shares. The acquisition adds two key endocrinology assets: Palsonify (paltusotine), a once-daily oral therapy for acromegaly approved by the FDA in September 2025 and the EMA in April 2026, and atumelnant, a Phase III candidate for congenital adrenal hyperplasia (CAH) with potential in Cushing's syndrome. The combined peak sales potential is projected to exceed $5 billion annually. Vertex plans to fund the acquisition with cash on hand and debt, supported by a $4.5 billion bridge financing from Bank of America and Morgan Stanley Senior Funding. The transaction is expected to close in Q3 2026, pending regulatory approvals and Crinetics shareholder consent.
Vertex to acquire Crinetics in $10B foray into endocrine disease drugs
Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals, paying $85 per share in cash, a 102% premium. This is Vertex's largest acquisition bet, aimed at expanding beyond its core cystic fibrosis franchise into endocrine disorders. Crinetics recently launched Palsonify for acromegaly, with early sales of $10 million in Q1 2026 and blockbuster potential. Crinetics also has atumelnant in late-stage development for congenital adrenal hyperplasia (CAH) and Cushing's syndrome, which Vertex believes could transform treatment. The deal, funded by cash and debt, is expected to close in Q3 2026 and is the fourth-largest biotech acquisition of the year.
Vertex to buy Crinetics for $10 billion to expand rare-disease business
Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals on July 6, 2026. The deal gives Vertex access to Palsonify, an FDA-approved oral therapy for acromegaly (a rare hormonal disorder), and atumelnant, an experimental drug for congenital adrenal hyperplasia (CAH). The companies project combined peak annual sales of over $5 billion for these drugs. Vertex will pay $85 per Crinetics share, with the deal expected to close in Q3 2026. Crinetics shares surged nearly 99% in extended trading, while Vertex shares fell slightly. Vertex expects the acquisition to add immediately to revenue growth and become accretive to non-GAAP operating income by 2029.